Greenyn Biotechnology Co (ROCO:6846) Ending Cash Position: NT$684.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6846 Greenyn Biotechnology Co Ltd ROCO:6846
68 GF Score
Price NT$58.20
GF Value NT$66.18
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Greenyn Biotechnology Co Ending Cash Position?

Greenyn Biotechnology Co ROCO:6846 +0.34% 68 Ending Cash Position is NT$684.2 Mil as of Jun. 2026. GuruFocus rates ROCO:6846 with a GF Score™ of 68/100 and a GF Value™ of NT$66.18 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Greenyn Biotechnology Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$684.2 Mil.

Greenyn Biotechnology Co's quarterly Ending Cash Position declined from Dec. 2025 (NT$793.4 Mil) to Mar. 2026 (NT$738.0 Mil) and declined from Mar. 2026 (NT$738.0 Mil) to Jun. 2026 (NT$684.2 Mil).

Greenyn Biotechnology Co's annual Ending Cash Position increased from Dec. 2023 (NT$533.5 Mil) to Dec. 2024 (NT$552.4 Mil) and increased from Dec. 2024 (NT$552.4 Mil) to Dec. 2025 (NT$793.4 Mil).

Greenyn Biotechnology Co Ending Cash Position Related Terms

Greenyn Biotechnology Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Greenyn Biotechnology Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenyn Biotechnology Co Ending Cash Position Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 356.13 370.30 533.51 552.38 793.36

Greenyn Biotechnology Co Quarterly Data
Sep22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 729.45 771.71 793.36 737.97 684.17
ROCO:6846
68GF Score
Greenyn Biotechnology Co Ltd ROCO:6846
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenyn Biotechnology Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Greenyn Biotechnology Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=552.383+240.977
=793.4

Greenyn Biotechnology Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=737.968+-53.794
=684.2

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$684.2 Mil mean?
Greenyn Biotechnology Co (ROCO:6846) has a Ending Cash Position of NT$684.2 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Greenyn Biotechnology Co and its competitors.
Is Greenyn Biotechnology Co's Ending Cash Position too high?
Greenyn Biotechnology Co's current Ending Cash Position is NT$684.2 Mil. Overall, Greenyn Biotechnology Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Greenyn Biotechnology Co's Ending Cash Position compare to VRTX and REGN?
Greenyn Biotechnology Co's Ending Cash Position of NT$684.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Greenyn Biotechnology Co and its competitors. Greenyn Biotechnology Co's current Ending Cash Position is NT$684.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenyn Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Greenyn Biotechnology Co (ROCO:6846) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$66.18, compared to a current price of NT$58.20 — trading 12.1% below its estimated fair value. The current Ending Cash Position is NT$684.2 Mil. Greenyn Biotechnology Co's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Greenyn Biotechnology Co (ROCO:6846), the current Ending Cash Position is NT$684.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Greenyn Biotechnology Co (ROCO:6846) Overvalued in 2026?

Based on GuruFocus' analysis, Greenyn Biotechnology Co stock appears to be undervalued. The current stock price of NT$58.20 is trading 12.1% below its estimated GF Value™ of NT$66.18. GuruFocus considers Greenyn Biotechnology Co to be Modestly Undervalued.

Key valuation signals for ROCO:6846:

  • Ending Cash Position: NT$684.2 Mil
  • GF Value™: NT$66.18 vs. price of NT$58.20 (12.1% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Greenyn Biotechnology Co Business Description

Address No 43 Keya Road, 5th Floor, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd is engaged in the business of health food raw materials production and sales of raw materials and production and sales of formula preparation.
68GF Score

Get the complete analysis for ROCO:6846

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$58.20
Price
NT$66.18
GF Value